贝伐单抗动脉介入超选化疗对大鼠脑胶质瘤的影响

doi:10.3969/j.issn.1004-616x.2018.01.012

癌变·畸变·突变 ›› 2018, Vol. 30 ›› Issue (1): 62-66.doi: 10.3969/j.issn.1004-616x.2018.01.012

贝伐单抗动脉介入超选化疗对大鼠脑胶质瘤的影响

高飞¹, 王英滨²

1. 中国医科大学附属第四医院, 辽宁沈阳 110032;
2. 沈阳医学院附属中心医院, 辽宁沈阳 110024

收稿日期:2017-09-11 修回日期:2017-10-24 出版日期:2018-01-30 发布日期:2018-01-30
作者简介:高飞,E-mail:gaofei1967@163.com
基金资助:
辽宁省自然科学基金项目（2014021100）

Experimental transcarotid artery chemotherapy on gliomas

GAO Fei¹, WANG Yingbin²

1. The 4^th Affiliated Hospital of China Medical University, Shenyang 110032;
2. The Affiliated Central Hospital of Shenyang Medical College, Shenyang 110024, Liaoning, China

Received:2017-09-11 Revised:2017-10-24 Online:2018-01-30 Published:2018-01-30

摘要/Abstract

摘要： 目的：探讨贝伐单抗动脉介入超选化疗对大鼠脑胶质瘤的影响。方法：移植脑胶质瘤大鼠模型建立成功后，随机分成对照组（经尾静脉注射等量生理盐水）、静脉注射顺铂组（V+CDDP）、静脉注射贝伐单抗组（V+BVZ）、动脉注射顺铂组（A+CDDP）、动脉注射贝伐单抗组（A+BVZ），给药（均为5 mg/kg）7 d后测量胶质瘤体积，并采用Real time-PCR和Western blot检测脑胶质瘤组织血管内皮生长因子（VEGF）、P21、Bcl-2和金属基质蛋白2（MMP-2）的mRNA和蛋白表达情况。结果：A+CDDP组肿瘤体积[（5.58±0.37）mm³]较V+CDDP组小[（7.67±0.70）mm³]，A+BVZ组肿瘤体积[（4.81±0.20）mm³]较V+BVZ组小[（6.57±0.69）mm³]，差异均具有统计学意义（P均 < 0.01）。同时，V+BVZ组肿瘤体积显著小于V+CDDP组（P < 0.01），A+BVZ组肿瘤体积显著小于A+CDDP组（P < 0.05），与静脉注射相比，动脉注射组VEGF、Bcl-2和MMP-2 mRNA和蛋白的表达均显著降低（P < 0.05），P21 mRNA和蛋白的表达显著升高（P < 0.05）。与注射CDDP相比，注射BVZ组VEGF、Bcl-2和MMP-2 mRNA和蛋白含量均显著降低（P < 0.05），P21 mRNA和蛋白表达均显著升高（P < 0.05）。结论：应用BVZ动脉介入超选化疗，能有效控制脑胶质瘤的大小，从而达到较好的治疗效果。

关键词: 脑胶质瘤, 动脉介入超选化疗, 贝伐单抗

Abstract: OBJECTIVE: To investigate the effectiveness of transcarotid artery chemotherapy on gliomas in rats. METHODS: After the brain glioma model was established successfully,rats were randomly divided into control group(the same amount of saline injected through the tail vein),intravenous injection of cisplatin group (V+CDDP),intravenous bevacizumab group (V+BVZ),arterial injection of cisplatin group (A+CDDP),arterial injection of bevacizumab group (A+BVZ). After treatment for 7 d,the glioma volume was detected,and the expression of VEGF,P21,Bcl-2 and MMP-2 protein and mRNA were detected by Western blot and real time-PCR. RESULTS: The glioma volume in A+CDDP group[(5.58±0.37) mm³] was smaller than that in V+CDDP group[(7.67±0.70) mm³]. The glioma volume in A+BVZ group[(4.81±0.20) mm³] was smaller than that in V+BVZ group[(6.57±0.69) mm³]. Differences were statistically significant (P < 0.01),and it was shown that artery injection had a strong inhibitory effect on the size of glioma. At the same time,the glioma volume in V+BVZ group was smaller than that in V+CDDP group (P < 0.01),the glioma volume in A+BVZ group was smaller than that in A+CDDP group (P < 0.05). BVZ had a stronger inhibitory effect on glioma size compared with CDDP,and artery injection had a stronger inhibitory effect than intravenous injection on the size of glioma. Compared with intravenous injection,the expression of VEGF,Bcl-2 and MMP-2 protein and mRNA were significantly decreased (P < 0.05) and the expression of P21 protein and mRNA was significantly increased in arterial injection group (P < 0.05). Compared with CDDP,the expression of VEGF,Bcl-2 and MMP-2 protein and mRNA were significantly decreased (P < 0.05) and the expression of P21 protein and mRNA was significantly increased (P < 0.05) in BVZ group. CONCLUSION: Application of BVZ transcatheter arterial chemoinfusion effectively inhibited the size of glioma,therefore,this approach may be useful for providing better therapeutic effect.

Key words: glioma, transcatheter arterial chemoinfusion, bevacizumab

中图分类号:

R730.5

高飞, 王英滨. 贝伐单抗动脉介入超选化疗对大鼠脑胶质瘤的影响[J]. 癌变·畸变·突变, 2018, 30(1): 62-66.

GAO Fei, WANG Yingbin. Experimental transcarotid artery chemotherapy on gliomas[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2018, 30(1): 62-66.

参考文献

[1] 陈圣攀,左晓坤,夏鹰. 脑胶质瘤的治疗进展[J]. 中华神经创伤外科电子杂志,2017,3(2):105-108.
[2] 唐涛,丁长青,孙祖杰,等. 高级别恶性脑胶质瘤术后三维适型放疗联合经颈动脉灌注化疗的效果分析[J]. 中国当代医药,2017,24(8):59-62.
[3] 颜元良,徐志杰,钱龙,等. 贝伐单抗联合放化疗治疗脑胶质瘤疗效的系统评价[J]. 中国临床药理学与治疗学,2016,21(1):64-70.
[4] 罗福祥,卢军,张海英,等. 新疆阿魏乙酸乙酯部位对小鼠S180实体瘤的抑制作用[J]. 中国药房,2016,27(31):4388-4391.
[5] 张雪鹏,孙影,张云鹏. 治疗大鼠颅内胶质瘤的实验研究[J]. 中国现代医学杂志,2013,23(17):11-16.
[6] 白俊利,王爱民,刘丽君,等. 经颈动脉灌注ACNU、VM-26联合治疗复发性脑胶质瘤的临床研究[J]. 解放军预防医学杂志,2016,34(4):85-86.
[7] TOMOKATSU H,KIYOAKI M,YOSHIKAZU S,et al. Influence of modes of ACNU administration on tissue and blood drug concentration in malignant brain tumors[J]. Neurosurg,1987,66:372-378.
[8] LUTZ R J,DEDRIEK R L,BORETOS J W,et al. Mixing studies during intraearotid artery infusions in an in vitro model[J]. Neurosurg,1986,64(2):277-283.
[9] 刘沣,刘健,杨华,等. 脑胶质瘤经颈内动脉灌注ACNU的疗效观察[J]. 中国微侵袭神经外科杂志,2006,11(5):228-229.
[10] 王昆鹏,赵文清,王维兴,等. 动脉灌注化疗对大鼠脑胶质瘤的治疗作用及其机制[J]. 吉林大学学报(医学版),2015,41(2):327-332.
[11] 曾志文,刘秋明,王红,等. 晚期乳腺癌介入治疗与全身化疗的疗效比较[J]. 当代医学,2017,23(18):136-137.
[12] 陈博年,吴剑涓. 脑胶质瘤的药物治疗[J]. 天津药学,2011,23(1):58-62.
[13] DESJARDINS A,REARDON D A,COAN A,et al. Bevacizumab and daily temozolomide for recurrent glioblastoma[J]. Cancer,2012,118(5):1302-1312.
[14] 徐彩虹,陈俊. 贝伐单抗联合吉非替尼片治疗非小细胞肺癌的临床研究[J]. 中国临床药理学杂志,2017,33(8):684-686.
[15] HACIBEKIROGLU I,KODAZ H,ERDOGAN B,et al. Single-agent bevacizumab is an effective treatment in recurrent glioblastoma[J]. Med Oncol,2015,32(2):460.
[16] NAGANE M,NISHIKAWA R,NARITA Y,et al. Phase Ⅱ study of single-agent bevacizumab in Japanese patients with recurrent malignant glioma[J]. Jpn J Clin Oncol,2012,42(10):887-895.
[17] 马庆防,黎军,王永楠,等. COX-2与MMP-9和VEGF在胶质瘤中的表达及意义[J]. 中华肿瘤防治杂志,2016:24-25.
[18] 董志强,李强,贺振华,等. P21和survivin蛋白在脑胶质瘤组织中的表达及其临床意义[J]. 吉林大学学报(医学版),2015,41(5):1004-1007,1106.
[19] 王芳,刘瑾. 重组人Bcl-2及Ercc-1基因腺病毒的构建及对肺癌细胞凋亡的影响[J]. 实用医学杂志,2015,31(5):2443-2446.
[20] 杨天权,王杭州,王勇强,等. NF-κB1通过促进BCL2表达抑制胶质瘤细胞的早期凋亡[J]. 临床神经外科杂志,2017,14(5):326-330.
[21] 高海东,寿记新,付旭东,等. ICAM-1、MMP-2在人脑胶质瘤的表达及相关性研究[J]. 中华神经医学杂志,2015,14(7):674-677.

贝伐单抗动脉介入超选化疗对大鼠脑胶质瘤的影响

Experimental transcarotid artery chemotherapy on gliomas

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 1

编辑推荐

Metrics

本文评价